CAMP CAMP4 Therapeutics Corporation
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
What changed
Recent filings, trades and movesA blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 1.78 |
| Cost of Equity (CAPM) | 14.07% |
| WACC | 13.98% |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -113.1% |
| Book / Price | 43.1% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -496.4% |
| Debt / Equity | 0.00 |
| Quality Score | 3/6 — normal (10y DCF) |
| SMA 50 | $3.84 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $3.82 |
| Bollinger Width / SMA20 | 37.3% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $0B |
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 23.8× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 22.6× · 3 peers |
| Peer P/B | $6.13 | 50% | median 3.6× · 4 peers |
| Peer P/S | $0.42 | 50% | median 4.5× · 3 peers |
| Market Anchor (SMA50) | $3.84 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.3B
- Employees
- 48
- List Date
- 2024-10-11
- CIK
- 0001736730
- Last Earnings
- Aug 13
- Headquarters
- Watertown, MA
- Homepage
- https://www.camp4tx.com
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 5.37% | -16.46% | 3.12% | -46.10% | -2.43% | -38.33% | -15.80% |
| Feb | 4.98% | 17.86% | -9.53% | -18.34% | 10.59% | 18.78% | 4.06% |
| Mar | -8.21% | 5.94% | -17.47% | 20.00% | -15.61% | -0.11% | -2.58% |
| Apr | 23.54% | -23.60% | -27.22% | -4.32% | -54.15% | -6.50% | -15.38% |
| May | 3.43% | 26.26% | -28.74% | -19.09% | 5.32% | 8.40% | -0.74% |
| Jun | -9.66% | -41.76% | -40.45% | -60.40% | -27.50% | 8.17% | -28.60% |
| Jul | -5.38% | 10.82% | -12.26% | -- | 20.74% | -19.95% | -1.21% |
| Aug | -6.13% | 25.87% | -34.52% | -- | -7.88% | -5.94% | -5.72% |
| Sep | -12.64% | -31.31% | -35.62% | -- | 92.31% | 6.60% | 3.87% |
| Oct | -5.96% | -3.31% | -42.07% | -0.84% | 41.02% | 3.13% | -1.34% |
| Nov | -6.33% | -5.50% | 38.33% | -52.34% | -3.55% | 8.61%* | -3.46% |
| Dec | -22.42% | 25.14% | -19.81% | 2.96% | 89.20% | -- | 15.01% |
| Total | -37.85% | -35.80% | -94.35% | -92.12% | 75.48% | -27.88% | -35.42% |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report
Executive Summary Overall Assessment: NEUTRAL (Confidence Level: 6/10) Key Drivers: Recent positive news headlines, improving momentum signals Primary Risks: High volatility, uncertain market context
Investment Thesis: CAMP's recent price action is driven by a mix of positive and neutral news sentiment. While the technical indicators suggest a consolidating trend, the options metrics hint at a potentially volatile near-term period.
Recent News Sentiment Impact: The stock has responded positively to recent news headlines, particularly those related to pipeline advancements and clinical trial updates. However, the overall market context remains uncertain, which may influence CAMP's price movements in the coming days.
Technical Analysis
- Trend Direction: Consolidating trend with a short-term uptrend
- Support/Resistance Levels: Key levels include $4.07 (SMA 50), $3.92 (SMA 20), and $5.26 (Upper Bollinger Band)
- Momentum Signals:
- RSI interpretation: Neutral (62.56) with no clear buy or sell signal
- MACD signal: Bullish momentum, indicating potential for continued price growth
- Bollinger Bands position: Squeeze, suggesting a possible breakout or mean reversion
- Volume Analysis: Volume SMA 20 indicates an increase in trading activity, while the OBV and volume rate of change suggest a neutral-to-bullish sentiment
News & Sentiment Analysis
- Recent Headlines Summary: Positive news headlines related to pipeline advancements and clinical trial updates
- Sentiment Assessment: Aggregate news sentiment is NEUTRAL with some positive undertones
- Catalyst Identification: Upcoming earnings release, potential catalysts for price movement
- Market Narrative: The market remains uncertain, which may influence CAMP's price movements in the coming days
Risk & Volatility Assessment
- Beta Interpretation: High risk relative to the market (beta = 1.65)
- Volatility Regime: Current volatility levels are high compared to historical averages
- Options Market Signals: Low IV rank, put/call ratios indicating neutral sentiment
- Downside Protection: Support levels include $3.92 (SMA 20) and $4.07 (SMA 50)
Market Context & Positioning
- Sector Performance: CAMP's sector is trending upward, providing a positive backdrop for the stock
- Institutional Activity: Institutional interest is moderate, with no clear buying or selling pressure
- Correlation Analysis: Correlation with the market is low (R-squared = 0.17), indicating limited dependence on broader market trends
- Relative Valuation: CAMP's relative valuation is reasonable, trading within a neutral range
Key Levels & Action Items
- Critical Price Levels: $4.07 (SMA 50) and $3.92 (SMA 20) are key support levels to monitor
- Breakout/Breakdown Levels: $5.26 (Upper Bollinger Band) is a potential breakout level, while $2.59 (Lower Bollinger Band) is a potential breakdown level
- Time-Sensitive Catalysts: Earnings release and pipeline updates are key catalysts for price movement
- Risk Management: Stop-loss levels can be set at $3.92 (SMA 20) to limit potential losses
Conclusion CAMP's recent price action is driven by a mix of positive and neutral news sentiment. While the technical indicators suggest a consolidating trend, the options metrics hint at a potentially volatile near-term period. The high volatility and uncertain market context pose risks for investors. A more cautious approach with risk management in place may be prudent.
CAMP Options Activity & IV Rank
Volatility Metrics
Options Flow · One expiry
ATM Options Pricing
Chain Summary
CAMP Implied Volatility
Loading implied volatility…
The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much CAMP actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
IV(call wing) − IV(ATM), in vol pointsThe same measure on the upside: how the OTM call is priced against the at-the-money strike.
- Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
- Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Loading the implied volatility surface…
Loading the implied volatility smile…
Risk Metrics
Analysis Details
Data Points: 251
Period: 252 trading days
High volatility - stock moves more than market
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $192K | #3505 of 3716 | -48.9% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
CAMP Institutional Ownership (13F)
Filings for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
CAMP Insider Trading (Form 4)
Latest: 2026-09-02| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-02 | Kelly Gold | Chief Financial Officer | Buy (P) | +10,000 | $3.96 | $39.6K | EDGAR |
| 2026-08-31 | Andrew J. Schwab | Director | Sell (S) | −400,000 | $4.04 | -$1.62M | EDGAR |
| 2026-08-26 | Andrew J. Schwab | Director | Sell (S) | −10 | $4.50 | -$45 | EDGAR |
| 2026-08-21 | Andrew J. Schwab | Director | Sell (S) | −191,865 | $4.59 | -$879.7K | EDGAR |
| 2026-08-19 | Daniel Tardiff | Chief Scientific Officer | Sell (S) | −1,738 | $4.76 | -$8.3K | EDGAR |
| 2026-08-05 | Josh Mandel-Brehm | Chief Executive Officer | Buy (P) | +6,551 | $1.65 | $10.8K | EDGAR |
| 2026-08-05 | Richard A Young | Director | Buy (P) | +16,378 | $1.65 | $27.0K | EDGAR |
| 2026-08-05 | Andrew J. Schwab | Director | Grant (A) | +3,179,558 RSU | — | EDGAR | |
| 2026-08-05 | 5AM Ventures VII, L.P. | 10%+ Owner | Buy (P) | +3,179,558 RSU | — | EDGAR | |
| 2026-08-05 | Kelly Gold | Chief Financial Officer | Buy (P) | +6,551 | $1.65 | $10.8K | EDGAR |
| 2026-08-05 | Yuri Maricich | Chief Medical Officer | Buy (P) | +6,551 | $1.65 | $10.8K | EDGAR |
| 2026-06-12 | Andrew J. Schwab | Director | Grant (A) | +28,000 opt | — | EDGAR | |
| 2026-06-12 | Amir Nashat | Director | Grant (A) | +28,000 opt | — | EDGAR | |
| 2026-06-12 | Richard A Young | Director | Grant (A) | +28,000 opt | — | EDGAR | |
| 2026-06-12 | Douglas E Williams | Director | Grant (A) | +28,000 opt | — | EDGAR |
CAMP Insider Holdings
9 insiders · @ $3.99| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | 5AM Ventures VI, L.P. | 10%+ Owner | 5,869,091 | $23.42M | $4.50M | 1 | 2025-09-15 |
| 2 | Andrew J. Schwab | Director | 5,277,216 | $21.06M | $7.50M | 8 | 2026-08-31 |
| 3 | Brian Chee | 10%+ Owner | 2,825,500 | $11.27M | $2.00M | 1 | 2025-09-11 |
| 4 | Josh Mandel-Brehm | Chief Executive Officer | 284,968 | $1.14M | $20.8K | 6 | 2026-08-05 |
| 5 | Amir Nashat | Director | 197,661 | $788.7K | $12.00M | 4 | 2026-06-12 |
| 6 | Richard A Young | Director | 186,388 | $743.7K | $52.0K | 5 | 2026-08-05 |
| 7 | Steven H Holtzman | Director | 108,946 | $434.7K | $0 | 3 | 2026-06-12 |
| 8 | Kelly Gold | Chief Financial Officer | 86,467 | $345.0K | $60.4K | 6 | 2026-09-02 |
| 9 | Yuri Maricich | Chief Medical Officer | 12,611 | $50.3K | $20.8K | 5 | 2026-08-05 |
CAMP Board & Officers
As of SEC filings through Sep 2, 2026Directors 9
- Amir Nashat · since Oct 10, 2024
- Andrew J. Schwab · since Oct 10, 2024
- Josh Mandel-Brehm · since Oct 10, 2024
- Michael J Higgins · since Oct 10, 2024
- Richard A Young · since Oct 10, 2024
- Steven H Holtzman · since Oct 10, 2024
- Douglas E Williams · since Mar 17, 2025
- Murray Stewart · since Mar 17, 2025
- Michael F MacLean · since Apr 1, 2026
Officers 4
- Josh Mandel-Brehm · Chief Executive Officer · since Oct 10, 2024
- Kelly Gold · Chief Financial Officer · since Oct 10, 2024
- Yuri Maricich · Chief Medical Officer · since Oct 10, 2024
- Daniel Tardiff · Chief Scientific Officer · since Oct 1, 2025
10% owners 1
- Amir Nashat · since Oct 10, 2024
Changes in the last 10 years (67)
| Aug 5, 2026 | Kush Parmar reported in an SEC filing no longer being a 10% owner |
| Aug 5, 2026 | Andrew J. Schwab no longer listed as a 10% owner in SEC filings |
| Aug 5, 2026 | 5AM Ventures VII, L.P. reported in an SEC filing no longer being a 10% owner |
| Aug 5, 2026 | 5AM Ventures VI, L.P. reported in an SEC filing no longer being a 10% owner |
| Aug 5, 2026 | 5AM Partners VII, LLC reported in an SEC filing no longer being a 10% owner |
| Aug 5, 2026 | 5AM Partners VI, LLC reported in an SEC filing no longer being a 10% owner |
| Aug 5, 2026 | 5AM Opportunities II, L.P. reported in an SEC filing no longer being a 10% owner |
| Aug 5, 2026 | 5AM Opportunities II (GP), LLC reported in an SEC filing no longer being a 10% owner |
| Apr 1, 2026 | Michael F MacLean became a director |
| Oct 1, 2025 | Daniel Tardiff became Chief Scientific Officer |
| Sep 15, 2025 | 5AM Ventures VII, L.P. first on file as a 10% owner |
| Sep 15, 2025 | 5AM Partners VII, LLC first on file as a 10% owner |
| Sep 11, 2025 | Polaris Partners X, L.P. reported in an SEC filing no longer being a 10% owner |
| Sep 11, 2025 | Polaris Partners VII, L.P. reported in an SEC filing no longer being a 10% owner |
| Sep 11, 2025 | Polaris Partners GP X, L.L.C. reported in an SEC filing no longer being a 10% owner |
| Sep 11, 2025 | Polaris Management Co. VII, L.L.C. reported in an SEC filing no longer being a 10% owner |
| Sep 11, 2025 | Polaris Entrepreneurs' Fund VII, L.P. reported in an SEC filing no longer being a 10% owner |
| Sep 11, 2025 | Brian Chee reported in an SEC filing no longer being a 10% owner |
| Sep 11, 2025 | Amy W Schulman reported in an SEC filing no longer being a 10% owner |
| Sep 9, 2025 | The company announced the departure of Ravi I. Thadhani from the board in an SEC filing |
| Sep 9, 2025 | The company announced the departure of Paula Ragan from the board in an SEC filing |
| Sep 9, 2025 | The company announced the departure of James P Boylan from the board in an SEC filing |
| Mar 17, 2025 | Murray Stewart became a director |
| Mar 17, 2025 | Douglas E Williams became a director |
| Oct 17, 2024 | Northpond Ventures III, LP first on file as a 10% owner |
| Oct 17, 2024 | Northpond Ventures III GP, LLC first on file as a 10% owner |
| Oct 17, 2024 | AH Equity Partners Bio IV, L.L.C. first on file as a 10% owner |
| Oct 17, 2024 | AH Bio Fund IV, L.P. first on file as a 10% owner |
| Oct 15, 2024 | Polaris Partners X, L.P. became a 10% owner |
| Oct 15, 2024 | Polaris Partners GP X, L.L.C. became a 10% owner |
| Oct 15, 2024 | Brian Chee became a 10% owner |
| Oct 15, 2024 | Amy W Schulman became a 10% owner |
| Oct 10, 2024 | Yuri Maricich became Chief Medical Officer |
| Oct 10, 2024 | Steven H Holtzman became a director |
| Oct 10, 2024 | Richard A Young became a director |
| Oct 10, 2024 | Ravi I. Thadhani became a director |
| Oct 10, 2024 | Polaris Partners VII, L.P. became a 10% owner |
| Oct 10, 2024 | Polaris Management Co. VII, L.L.C. became a 10% owner |
| Oct 10, 2024 | Polaris Entrepreneurs' Fund VII, L.P. became a 10% owner |
| Oct 10, 2024 | Paula Ragan became a director |
| Oct 10, 2024 | Northpond Ventures, LP became a 10% owner |
| Oct 10, 2024 | Northpond Ventures II, LP became a 10% owner |
| Oct 10, 2024 | Northpond Ventures II GP, LLC became a 10% owner |
| Oct 10, 2024 | Northpond Ventures GP, LLC became a 10% owner |
| Oct 10, 2024 | Michael P. Rubin became a 10% owner |
| Oct 10, 2024 | Michael J Higgins became a director |
| Oct 10, 2024 | Marc L Andreessen became a 10% owner |
| Oct 10, 2024 | Kush Parmar became a 10% owner |
| Oct 10, 2024 | Kelly Gold became Chief Financial Officer |
| Oct 10, 2024 | Josh Mandel-Brehm became a director |
| Oct 10, 2024 | Josh Mandel-Brehm became Chief Executive Officer |
| Oct 10, 2024 | James P Boylan became a director |
| Oct 10, 2024 | Ingo Chakravarty became a director |
| Oct 10, 2024 | Everest Aggregator, LP became a 10% owner |
| Oct 10, 2024 | Enavate Sciences GP, LLC became a 10% owner |
| Oct 10, 2024 | David Bumcrot became Chief Scientific Officer |
| Oct 10, 2024 | Benjamin A Horowitz became a 10% owner |
| Oct 10, 2024 | Andrew J. Schwab became a director |
| Oct 10, 2024 | Andrew J. Schwab became a 10% owner |
| Oct 10, 2024 | Amir Nashat became a director |
| Oct 10, 2024 | Amir Nashat became a 10% owner |
| Oct 10, 2024 | AH Equity Partners Bio I, L.L.C. became a 10% owner |
| Oct 10, 2024 | AH Bio Fund I, L.P. became a 10% owner |
| Oct 10, 2024 | 5AM Ventures VI, L.P. became a 10% owner |
| Oct 10, 2024 | 5AM Partners VI, LLC became a 10% owner |
| Oct 10, 2024 | 5AM Opportunities II, L.P. became a 10% owner |
| Oct 10, 2024 | 5AM Opportunities II (GP), LLC became a 10% owner |
- Prev
- 1
Not reported recently (17)
- David Bumcrot · Last reported as Chief Scientific Officer in an SEC filing dated Apr 3, 2025
- Everest Aggregator, LP · Last reported as a 10% owner in an SEC filing dated Oct 17, 2024
- Northpond Ventures, LP · Last reported as a 10% owner in an SEC filing dated Oct 17, 2024
- Enavate Sciences GP, LLC · Last reported as a 10% owner in an SEC filing dated Oct 17, 2024
- Northpond Ventures II, LP · Last reported as a 10% owner in an SEC filing dated Oct 17, 2024
- AH Bio Fund I, L.P. · Last reported as a 10% owner in an SEC filing dated Oct 17, 2024
- Marc L Andreessen · Last reported as a 10% owner in an SEC filing dated Oct 17, 2024
- Michael P. Rubin · Last reported as a 10% owner in an SEC filing dated Oct 17, 2024
- Benjamin A Horowitz · Last reported as a 10% owner in an SEC filing dated Oct 17, 2024
- Northpond Ventures GP, LLC · Last reported as a 10% owner in an SEC filing dated Oct 17, 2024
- AH Equity Partners Bio I, L.L.C. · Last reported as a 10% owner in an SEC filing dated Oct 17, 2024
- Northpond Ventures II GP, LLC · Last reported as a 10% owner in an SEC filing dated Oct 17, 2024
- Northpond Ventures III GP, LLC · Last reported as a 10% owner in an SEC filing dated Oct 17, 2024
- Northpond Ventures III, LP · Last reported as a 10% owner in an SEC filing dated Oct 17, 2024
- AH Bio Fund IV, L.P. · Last reported as a 10% owner in an SEC filing dated Oct 17, 2024
- AH Equity Partners Bio IV, L.L.C. · Last reported as a 10% owner in an SEC filing dated Oct 17, 2024
- Ingo Chakravarty · Last reported as a director in an SEC filing dated Oct 10, 2024
CAMP Proposed Insider Sales (Form 144)
Latest: 2026-08-19What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-19 | Daniel Tardiff | affiliate | 1,738 | $8.3K | 2026-08-19 | J.P. Morgan Securities LLC | — | EDGAR |
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-05 | Financial statements and exhibits | EDGAR |
| 2026-09-28 | Regulation FD disclosure · Other events | EDGAR |
| 2026-08-13 | Earnings results | EDGAR |
| 2026-08-04 | Material agreement · Unregistered share sale · Regulation FD disclosure | EDGAR |
| 2026-07-27 | Regulation FD disclosure · Other events | EDGAR |
| 2026-06-12 | Director or officer change · Shareholder vote results | EDGAR |
| Filing Date | Accession | Link |
|---|
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $5.0M | — | 2026-10-31 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.00% | $2.9M | $75.0B | 2026-11-17 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $2.0M | — | 2026-10-31 |
| 4 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.01% | $1.2M | $13.5B | 2026-11-17 |
| 5 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.00% | $740,861 | — | 2026-10-31 |
| 6 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.03% | $382,452 | $1.2B | 2026-11-17 |
| 7 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.02% | $211,348 | $1.0B | 2026-11-17 |
| 8 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.01% | $136,299 | — | 2026-10-31 |
| 9 | RSSL Global X Russell 2000 ETF | Global X | 0.01% | $61,844 | — | 2026-11-18 |
| 10 | OMFS Invesco Russell 2000 Dynamic Multifactor ETF | Invesco | 0.01% | $20,424 | — | 2026-11-17 |
| 11 | IBRN iShares Neuroscience and Healthcare ETF | iShares (BlackRock) | 0.23% | $19,180 | $8.2M | 2026-11-17 |
| 12 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $14,703 | — | 2026-10-31 |
| 13 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.00% | $7,298 | — | 2026-11-18 |
| 14 | URTY ProShares UltraPro Russell2000 | ProShares | 0.00% | $5,104 | — | 2026-11-18 |
| 15 | UWM ProShares Ultra Russell2000 | ProShares | 0.00% | $3,370 | — | 2026-11-18 |
| 16 | FSEG Fidelity Enhanced Small Cap Growth ETF | Fidelity | 0.02% | $1,860 | $7.5M | 2026-11-17 |
| 17 | HDG ProShares Hedge Replication ETF | ProShares | 0.00% | $160 | — | 2026-11-18 |
| 18 | RB ProShares Russell 2000 Dynamic Buffer ETF | ProShares | 0.00% | $53 | — | 2026-11-18 |
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $1.90M | $-28.96M | $-0.37 | $-8.16M |
| Q2 '26 | 2026-06-30 | $1.78M | $-33.53M | $-0.58 | $-12.69M |
| Q1 '26 | 2026-03-31 | $1.29M | $-18.33M | $-0.32 | $-10.98M |
| Q4 '25 | 2025-12-31 | $348.00K | $-40.28M | $-0.75 | $6.29M |
| Q3 '25 | 2025-09-30 | $795.00K | $-15.10M | $-0.55 | $-11.22M |
| Q2 '25 | 2025-06-30 | $1.50M | $-12.59M | $-0.62 | $-10.34M |
| Q1 '25 | 2025-03-31 | $858.00K | $-12.43M | $-0.62 | $-14.29M |
| Q4 '24 | 2024-12-31 | $652.00K | $-13.28M | $65.46 | $-11.29M |
| Q2 '24 | 2023-08-31 | $61.71M | $-4.22M | $-0.11 | $7.14M |
| Q1 '24 | 2023-05-31 | $70.89M | $-4.03M | $-0.11 | $-2.98M |
| Q4 '23 | 2023-02-28 | $78.51M | $-8.09M | $-0.22 | $-1.09M |
| Q3 '23 | 2022-11-30 | $78.89M | $-4.73M | $-0.13 | $31.67M |
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
CAMP vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| ARGX argenx SE American Depositary Shares | $59.2B | — | — | +12.4% | 90 |
| BIIB Biogen Inc. Common Stock | $37.2B | 105.9 | +2.3% | +39.3% | 100 |
| NBIX Neurocrine Biosciences Inc | $16.5B | 23.3 | +38.0% | +11.6% | 39 |
| PRAX Praxis Precision Medicines, Inc. Common | $8.5B | — | — | +9.6% | 100 |
| ALKS Alkermes Inc. plc | $7.9B | — | +15.3% | +63.9% | 84 |
| PTCT PTC Therapeutics, Inc. | $5.0B | — | −35.1% | −23.7% | 30 |
| EWTX Edgewise Therapeutics, Inc. Common Stock | $4.5B | 5.0 | — | +73.4% | 65 |
| AXGN Axogen, Inc. Common Stock | $3.4B | — | +24.3% | +81.7% | 22 |
| CAMP CAMP4 Therapeutics Corporation Common St | $257M | — | +39.9% | −33.5% | — |
| Peer median | $8.2B | 23.3 | +15.3% | +25.9% | 74 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.